PhRMA Statement on FTC Settlement with Express Scripts

WASHINGTON, D.C. (February 6, 2026) - Today, Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President of Media Relations Chanse Jones issued the following statement regarding the FTC settlement with Express Scripts:

"The proposed consent agreement between the FTC and Express Scripts underscores the broad consensus that PBM middlemen have been using opaque practices to drive up medicine costs. The agreement follows recent legislation passed by Congress to rein in PBM practices and a new Department of Labor proposed rule that would require greater transparency into PBM compensation. Collectively, these actions reflect growing bipartisan urgency to impose more accountability and oversight to PBM and insurer practices to lower medicine costs for patients."

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. PhRMA member companies have invested more than $850 billion in the search for new treatments and cures over the last decade, supporting nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.Innovation.org
www.VotersforCures.org
www.MAT.org
www.LinkedIn.com/Company/PhRMA
www.X.com/PhRMA